Syed Abbas Ali

Research output

Research output per year 2009 2019 2020 2021 2022 2024

• 22 Article
• 2 Letter
• 2 Review article

Research output per year

Research output per year

Search results

• 2024

  Coexistence of Light Chain and Transthyretin Cardiac Amyloidosis

  Gami, A., Woller, J., Scheel, P., Ali, S. A., Huff, C. A., Steenbergen, C., Halushka, M., Sharma, K., Polydefkis, M. & Vaishnav, J., Apr 3 2024, In: JACC: Case Reports. 29, 7, 102285.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Amyloidosis, Hereditary, Transthyretin-Related 100%
  • Prealbumin 79%
  • Amyloidosis 71%
  • Amyloid 60%
  • Light 45%
• 2023

  Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years

  Webster, J. A., Reed, M., Tsai, H. L., Ambinder, A., Jain, T., Dezern, A. E., Levis, M. J., Showel, M. M., Prince, G. T., Hourigan, C. S., Gladstone, D. E., Bolanos-Meade, J., Gondek, L. P., Ghiaur, G., Dalton, W. B., Paul, S., Fuchs, E. J., Gocke, C. B., Ali, S. A., Huff, C. A., & 10 othersBorrello, I. M., Swinnen, L., Wagner-Johnston, N., Ambinder, R. F., Luznik, L., Gojo, I., Smith, B. D., Varadhan, R., Jones, R. J. & Imus, P. H., Mar 2023, In: Transplantation and Cellular Therapy. 29, 3, p. 182.e1-182.e8

  Research output: Contribution to journal › Article › peer-review

  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 100%
  • Cyclophosphamide 95%
  • Transplantation 77%
  • Bone Marrow 74%
  • Survival 35%

• Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source

  Sterling, C. H., Hughes, M. S., Tsai, H. L., Yarkony, K., Fuchs, E. J., Swinnen, L. J., Paul, S., Bolaños-Meade, J., Luznik, L., Imus, P. H., Ali, S. A., Jain, T., Ambinder, A., DeZern, A., Huff, C. A., Gocke, C. B., Varadhan, R., Wagner-Johnston, N., Jones, R. J. & Ambinder, R. F., Apr 2023, In: Transplantation and Cellular Therapy. 29, 4, p. 267.e1-267.e5

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Peripheral T-Cell Lymphoma 100%
  • Cyclophosphamide 67%
  • Transplantation 55%
  • Bone Marrow 53%
  • Transplants 45%
• 2022

  Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel

  Porter, T. J., Lazarevic, A., Ziggas, J. E., Fuchs, E., Kim, K., Byrnes, H., Luznik, L., Bolaños-Meade, J., Ali, S. A., Shah, N. N., Wagner-Johnston, N. & Jain, T., Dec 2022, In: British journal of haematology. 199, 5, p. 720-727 8 p.

  Research output: Contribution to journal › Article › peer-review

  • axicabtagene ciloleucel 100%
  • Hemophagocytic Lymphohistiocytosis 67%
  • Cytokine Release Syndrome 41%
  • INCB018424 39%
  • Interleukin 1 Receptor Antagonist Protein 34%

• Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study

  Hughes, M. S., Sterling, C. H., Varadhan, R., Ambinder, R. F., Jones, R. J., Sweren, R. J., Rozati, S., Bolaños-Meade, J., Luznik, L., Imus, P. H., Ali, S. A., Borrello, I. M., Huff, C. A., T, J., Ambinder, A., DeZern, A. E., Gocke, C. B., Gladstone, D. E., Swinnen, L. J., Wagner-Johnston, N. D., & 1 othersFuchs, E. J., 2022, In: Leukemia and Lymphoma. 63, 12, p. 2987-2991 5 p.

  Research output: Contribution to journal › Letter › peer-review

• Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience

  Ambinder, A., Smith, M., Tsai, H. L., Varadhan, R., DeZern, A., Dalton, W., Gocke, C., Webster, J., Gondek, L., Gojo, I., Ali, S. A., Huff, C. A., Swinnen, L., Wagner-Johnston, N., Showel, M., Prince, G., Borrello, I., Bolaños-Meade, J., Luznik, L., Jain, T., & 8 othersImus, P., Fuchs, E., Ambinder, R., Gladstone, D. E., Levis, M., Jones, R., Ghiaur, G. & Smith, B. D., Apr 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, 4, p. 260-269 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Homologous Transplantation 100%
  • Acute Myeloid Leukemia 84%
  • Cyclophosphamide 82%
  • Transplants 55%
  • Mutation 49%

• Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis

  Jain, T., Tsai, H. L., DeZern, A. E., Gondek, L. P., Elmariah, H., Bolaños-Meade, J., Luznik, L., Fuchs, E., Ambinder, R., Gladstone, D. E., Imus, P., Webster, J., Prince, G., Ghiaur, G., Smith, B. D., Ali, S. A., Ambinder, A., Dalton, W. B., Gocke, C. B., Huff, C. A., & 7 othersGojo, I., Swinnen, L., Wagner-Johnston, N., Borrello, I., Varadhan, R., Levis, M. & Jones, R. J., May 2022, In: Transplantation and Cellular Therapy. 28, 5, p. 259.e1-259.e11

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Primary Myelofibrosis 100%
  • Graft vs Host Disease 84%
  • Cyclophosphamide 74%
  • Transplantation 60%
  • Bone Marrow 58%
• 2021

  Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma

  Sterling, C. H., Tsai, H. L., Holdhoff, M., Bolaños-Meade, J., Luznik, L., Fuchs, E. J., Huff, C. A., Gocke, C. B., Ali, S. A., Borrello, I. M., Varadhan, R., Jones, R. J., Gladstone, D. E., Ambinder, R. F., Wagner-Johnston, N., Swinnen, L. J. & Imus, P. H., Oct 2021, In: Transplantation and Cellular Therapy. 27, 10, p. 863.e1-863.e5

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Graft vs Host Disease 100%
  • Cyclophosphamide 88%
  • Lymphoma 78%
  • Transplantation 72%
  • Central Nervous System 70%

• An Allogeneic Multiple Myeloma GM-CSF-Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission

  Biavati, L., Ann Huff, C., Ferguson, A., Sidorski, A., Stevens, M. A., Rudraraju, L., Zucchinetti, C., Abbas Ali, S., Imus, P., Gocke, C. B., Gittelman, R. M., Johnson, S., Sanders, C., Vignali, M., Gandhi, A., Ye, X., Noonan, K. A. & Borrello, I., Dec 15 2021, In: Clinical Cancer Research. 27, 24, p. 6696-6708 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lenalidomide 100%
  • Granulocyte-Macrophage Colony-Stimulating Factor 78%
  • Multiple Myeloma 74%
  • Immunity 61%
  • Vaccines 56%

• Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma

  Atrash, S., Ali, S. A. & Usmani, S. Z., Jan 2021, In: Clinical Lymphoma, Myeloma and Leukemia. 21, 1, p. 21-34 14 p.

  Research output: Contribution to journal › Review article › peer-review

  • Chimeric Antigen Receptors 100%
  • Multiple Myeloma 73%
  • Cell- and Tissue-Based Therapy 70%
  • T-Lymphocytes 45%
  • B-Cell Maturation Antigen 18%
  1 Scopus citations

• Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide

  Rappazzo, K. C., Zahurak, M., Bettinotti, M., Ali, S. A., Ambinder, A. J., Bolaños-Meade, J., Borrello, I., Dezern, A. E., Gladstone, D., Gocke, C., Fuchs, E., Huff, C. A., Imus, P. H., Jain, T., Luznik, L., Rahmat, L., Swinnen, L. J., Wagner-Johnston, N., Jones, R. J. & Ambinder, R. F., Nov 2021, In: Transplantation and Cellular Therapy. 27, 11, p. 909.e1-909.e6

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Graft vs Host Disease 100%
  • Peripheral Blood Stem Cell Transplantation 97%
  • Cyclophosphamide 88%
  • Unrelated Donors 73%
  • Transplantation 72%
• 2020

  Allogeneic transplantation for Ph¹ acute lymphoblastic leukemia with posttransplantation cyclophosphamide

  Webster, J. A., Luznik, L., Tsai, H. L., Imus, P. H., DeZern, A. E., Pratz, K. W., Levis, M. J., Gojo, I., Showel, M. M., Prince, G., Bolaños-Meade, J., Gondek, L. P., Ghiaur, G., Dalton, W. B., Jain, T., Fuchs, E. J., Gladstone, D. E., Gocke, C. B., Ali, S. A., Huff, C. A., & 6 othersBorrello, I. M., Swinnen, L., Wagner-Johnston, N., Ambinder, R. F., Jones, R. J. & Smith, B. D., Oct 20 2020, In: Blood Advances. 4, 20, p. 5078-5088 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Homologous Transplantation 100%
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 86%
  • Cyclophosphamide 82%
  • Bone Marrow 64%
  • Graft vs Host Disease 56%
  3 Scopus citations

• CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity

  Kararoudi, M. N., Nagai, Y., Elmas, E., Pereira, M. D. S. F., Ali, S. A., Imus, P. H., Wethington, D., Borrello, I. M., Lee, D. A. & Ghiaur, G., Nov 19 2020, In: Blood. 136, 21, p. 2416-2427 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • daratumumab 100%
  • Effector 64%
  • All-Trans-Retinoic Acid 57%
  • Natural Killer Cells 54%
  • Multiple Myeloma 51%
  5 Scopus citations

• Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide

  DeZern, A. E., Elmariah, H., Zahurak, M., Rosner, G. L., Gladstone, D. E., Ali, S. A., Huff, C. A., Swinnen, L. J., Imus, P., Borrello, I., Wagner-Johnston, N. D., Ambinder, R. F., Brodsky, R. A., Cooke, K., Luznik, L., Fuchs, E. J., Bolaños-Meade, J. & Jones, R. J., Nov 2020, In: Biology of Blood and Marrow Transplantation. 26, 11, p. 2075-2081 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Duration of Therapy 100%
  • Cyclophosphamide 99%
  • Immunosuppressive Agents 88%
  • Immunosuppression 88%
  • Transplantation 81%
  3 Scopus citations

• Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis

  Imus, P. H., Tsai, H. L., DeZern, A. E., Jerde, K., Swinnen, L. J., Bolaños-Meade, J., Luznik, L., Fuchs, E. J., Wagner-Johnston, N., Huff, C. A., Gladstone, D. E., Ambinder, R. F., Gocke, C. B., Ali, S. A., Borrello, I. M., Varadhan, R., Brodsky, R. & Jones, R. J., Dec 2020, In: Biology of Blood and Marrow Transplantation. 26, 12, p. 2306-2310 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Thrombotic Microangiopathies 100%
  • Graft vs Host Disease 77%
  • Cyclophosphamide 68%
  • Transplantation 56%
  • Transplants 32%
  1 Scopus citations

• Use of Bone-Modifying Agents among Medicare Beneficiaries with Multiple Myeloma

  Gupta, A., Wang, P., Ali, S. A., Rajkumar, S. V., Gyawali, B., Overton, H. N. & Makary, M. A., Feb 2020, In: JAMA Oncology. 6, 2, p. 296-298 3 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  2 Scopus citations
• 2019

  Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial

  Bolaños-Meade, J., Cooke, K. R., Gamper, C. J., Ali, S. A., Ambinder, R. F., Borrello, I. M., Fuchs, E. J., Gladstone, D. E., Gocke, C. B., Huff, C. A., Luznik, L., Swinnen, L. J., Symons, H. J., Terezakis, S. A., Wagner-Johnston, N., Jones, R. J. & Brodsky, R. A., Apr 2019, In: The Lancet Haematology. 6, 4, p. e183-e193

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Haploidentical Transplantation 100%
  • Hemoglobinopathies 80%
  • Whole-Body Irradiation 72%
  • Clinical Trials 40%
  • Transplants 38%
  39 Scopus citations

• Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70

  Imus, P. H., Tsai, H. L., Luznik, L., Fuchs, E. J., Huff, C. A., Gladstone, D. E., Lowery, P., Ambinder, R. F., Borrello, I. M., Swinnen, L. J., Wagner-Johnston, N., Gocke, C. B., Abbas Ali, S., Bolaños-Meade, F. J., Varadhan, R. & Jones, R. J., Sep 10 2019, In: Blood Advances. 3, 17, p. 2608-2616 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Haploidentical Transplantation 100%
  • Graft vs Host Disease 65%
  • Cyclophosphamide 57%
  • Mortality 31%
  • Incidence 18%
  3 Scopus citations

• Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation

  Imus, P. H., Blackford, A. L., Bettinotti, M., Luznik, L., Fuchs, E. J., Huff, C. A., Gladstone, D. E., Ambinder, R. F., Borrello, I. M., Fuchs, R. J., Swinnen, L. J., Wagner-Johnston, N., Gocke, C. B., Ali, S. A., Bolaños-Meade, F. J., Jones, R. J. & Dezern, A. E., Dec 2019, In: Biology of Blood and Marrow Transplantation. 25, 12, p. 2431-2437 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cytokine Release Syndrome 100%
  • Peripheral Blood Stem Cell Transplantation 82%
  • Transplantation 23%
  • Odds Ratio 5%
  • Confidence Intervals 5%
  14 Scopus citations
• 2018

  Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non–First-Degree Related Donors

  Elmariah, H., Kasamon, Y. L., Zahurak, M., Macfarlane, K. W., Tucker, N., Rosner, G. L., Bolaños-Meade, J., Fuchs, E. J., Wagner-Johnston, N., Swinnen, L. J., Huff, C. A., Matsui, W. H., Gladstone, D. E., McCurdy, S. R., Borrello, I., Gocke, C. B., Shanbhag, S., Cooke, K. R., Ali, S. A., Brodsky, R. A., & 4 othersDeZern, A. E., Luznik, L., Jones, R. J. & Ambinder, R. F., May 2018, In: Biology of Blood and Marrow Transplantation. 24, 5, p. 1099-1102 4 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Haploidentical Transplantation 100%
  • Bone Marrow Transplantation 63%
  • Cyclophosphamide 57%
  • Tissue Donors 48%
  • Transplants 38%
  27 Scopus citations

• T cells genetically modified to express an anti–B-Cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma

  Brudno, J. N., Maric, I., Hartman, S. D., Rose, J. J., Wang, M., Lam, N., Stetler-Stevenson, M., Salem, D., Yuan, C., Pavletic, S., Kanakry, J. A., Ali, S. A., Mikkilineni, L., Feldman, S. A., Stroncek, D. F., Hansen, B. G., Lawrence, J., Patel, R., Hakim, F., Gress, R. E., & 1 othersKochenderfer, J. N., Aug 1 2018, In: Journal of Clinical Oncology. 36, 22, p. 2267-2280 14 p.

  Research output: Contribution to journal › Article › peer-review

  • B-Cell Maturation Antigen 100%
  • Chimeric Antigen Receptors 96%
  • Multiple Myeloma 70%
  • Antigens 45%
  • T-Lymphocytes 44%
  237 Scopus citations
• 2016

  IQGAP1 scaffold-MAP kinase interactions enhance multiple myeloma clonogenic growth and self-renewal

  Gocke, C. B., McMillan, R., Wang, Q., Begum, A., Penchev, V. R., Ali, S. A., Borrello, I., Huff, C. A. & Matsui, W., Nov 2016, In: Molecular cancer therapeutics. 15, 11, p. 2733-27339 24607 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • IQ motif containing GTPase activating protein 1 100%
  • Multiple Myeloma 54%
  • Phosphotransferases 42%
  • Growth 27%
  • WW Domains 17%
  6 Scopus citations

• T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

  Ali, S. A., Shi, V., Maric, I., Wang, M., Stroncek, D. F., Rose, J. J., Brudno, J. N., Stetler-Stevenson, M., Feldman, S. A., Hansen, B. G., Fellowes, V. S., Hakim, F. T., Gress, R. E. & Kochenderfer, J. N., Sep 29 2016, In: Blood. 128, 13, p. 1688-1700 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • B-Cell Maturation Antigen 100%
  • Chimeric Antigen Receptors 77%
  • Multiple Myeloma 56%
  • Antigen 47%
  • T-Lymphocytes 35%
  359 Scopus citations
• 2015

  Class act: Safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma

  Burotto, M., Ali, S. A. & O'sullivan Coyne, G., Jan 1 2015, In: Expert Opinion on Drug Safety. 14, 1, p. 97-110 14 p.

  Research output: Contribution to journal › Review article › peer-review

  • Afatinib 100%
  • Erlotinib Hydrochloride 83%
  • Gefitinib 82%
  • Protein-Tyrosine Kinases 79%
  • Non-Small Cell Lung Carcinoma 78%
  8 Scopus citations

• High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses

  Mossoba, M. E., Halverson, D. C., Kurlander, R., Schuver, B. B., Carpenter, A., Hansen, B., Steinberg, S. M., Ali, S. A., Tageja, N., Hakim, F. T., Gea-Banacloche, J., Sportes, C., Hardy, N. M., Hickstein, D. D., Pavletic, S. Z., Khuu, H., Sabatini, M., Stroncek, D., Levine, B. L., June, C. H., & 6 othersMariotti, J., Rixe, O., Fojo, A. T., Bishop, M. R., Gress, R. E. & Fowler, D. H., Oct 1 2015, In: Clinical Cancer Research. 21, 19, p. 4312-4320 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Pentostatin 100%
  • Chimerism 82%
  • Sirolimus 69%
  • Cyclophosphamide 61%
  • Transplants 41%
  5 Scopus citations
• 2009

  Pancreatic plasmacytoma presenting as variceal hemorrhage: Life threatening complication of a rare entity

  Atiq, M., Ali, S. A., Dang, S., Krishna, S. G., Anaisse, E., Olden, K. W. & Aduli, F., 2009, In: Journal of the Pancreas. 10, 2, p. 187-188 2 p.

  Research output: Contribution to journal › Article › peer-review

  • Plasmacytoma 100%
  • Esophageal and Gastric Varices 96%
  • Hemorrhage 51%
  • Jaundice 41%
  • Pancreatitis 38%
  8 Scopus citations